HAMPTON, N.J., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,050,000 additional shares of common stock at the public offering price of $24.50. Proceeds to Celldex from the exercise of the underwriters' option will be approximately $18.9 million, after deducting underwriting discounts and commissions and proceeds to a limited number of selling stockholders. 813,483 shares sold pursuant to the exercise of the option were sold by Celldex and 236,517 shares were sold by selling stockholders. The offering is expected to close on or about December 10, 2013, subject to customary closing conditions.
Jefferies LLC and Leerink Swann LLC are acting as joint book-running managers of the offering. Guggenheim Securities, Oppenheimer & Co. Inc., Wedbush PacGrow Life Sciences, Brean Capital, LLC, Cantor Fitzgerald & Co. and Roth Capital Partners are acting as co-managers of the offering.
Celldex anticipates using the net proceeds from the offering to fund Celldex's clinical trials of its product candidates and for working capital and other general corporate purposes. The 236,517 shares sold by selling stockholders relate to stock options held by one officer and three directors, which stock options would otherwise have expired within the next 15 months. A shelf registration statement relating to the shares was filed with the SEC and is effective. A final prospectus supplement related to the offering has also been filed and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 or by email at Syndicate@Leerink.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.